Thrombospondin-2 as a Biomarker of Advanced Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)
), Fatikha Rudia Ahda(2),
(1) Division of Gastroenterohepatology, Department of Internal Medicine, Faculty of Medicine, Universitas Mataram/ General National Hospital, NTB
(2) Faculty of Medicine, Universitas Mataram/ General National Hospital, NTB
Corresponding Author
Abstract
Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) is a highly prevalent liver disorder associated with obesity and metabolic syndrome, replacing the term Non-Alcoholic Fatty Liver Disease (NAFLD). The diagnosis of MAFLD is established based on the presence of hepatic steatosis accompanied by metabolic abnormalities such as overweight/obesity, type 2 diabetes mellitus, or metabolic dysregulation. Although liver biopsy remains the gold standard for diagnosis, its invasive nature underscores the need for practical, non-invasive biomarkers. This review aims to summarize the current evidence regarding thrombospondin-2 (TSP-2) as a potential biomarker of hepatic fibrosis in MAFLD. Recent data indicate that serum TSP-2 levels correlate with the severity of steatosis, inflammation, and fibrosis. TSP-2 also shows promise in distinguishing simple steatosis from steatohepatitis and in identifying patients at risk of advanced fibrosis. While these findings highlight the potential role of TSP-2 in diagnosis and disease monitoring, further clinical validation is required before its routine implementation in clinical practice.
Keywords
References
Zheng M-H, Pan J-W, Lu J-Q, et al. A meta-analysis and systematic review of 10 739 607 individuals: overall prevalence of MAFLD was 38.77% (95% CI 32.94-44.95). J Clin Endocrinol Metab. 2024;107(9):2691-2702.
Eslam M, Sarin SK, Wong VWS, et al. Asian Pacific Association for the Study of the Liver Clinical Practice Guidelines for the diagnosis and management of metabolic dysfunction-associated fatty liver disease (MAFLD). Hepatol Int. 2020;14(6):889-919.
Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with NAFLD. Gastroenterology. 2015;149(2):389–97.
Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology. 2009;49(3):1017–44.
Mak JHC, Lui DTW, Fong CHY, Cheung CYY, Wong Y, Lee ACH, et al. Serum thrombospondin-2 level changes with liver stiffness improvement in patients with type 2 diabetes. Clin Endocrinol (Oxf). 2024;100(3):230–7.
Bornstein P. Thrombospondins: structure and regulation of expression. FASEB J. 1992;6(14):3290–9.
Calabro NE, Kristofik NJ, Kyriakides TR. Thrombospondin-2 and extracellular matrix assembly. Biochim Biophys Acta. 2014;1840(8):2396–402.
Lee CH, Seto WK, Lui DTW, Fong CHY, Wan HY, Cheung CYY, et al. Circulating thrombospondin-2 as a novel fibrosis biomarker of NAFLD in type 2 diabetes. Diabetes Care. 2021;44(9):2089–97.
Kozumi K, Kodama T, Murai H, Sakane S, Govaere O, Cockell S, et al. Transcriptomics identify thrombospondin-2 as a biomarker for NASH and advanced liver fibrosis. Hepatology. 2021;74(5):2452–66.
Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52(5):1836–46.
Xu R, Tao A, Zhang S, Deng Y, Chen G. Roles of NLRP3 inflammasome in liver diseases: focusing on nonalcoholic fatty liver disease. Front Immunol. 2020;11:609924.
Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol. 2006;6(10):772–83.
Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of metabolic dysfunction-associated fatty liver disease. Nat Rev Gastroenterol Hepatol. 2021;18(6):387–400.
Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut–liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018;15(7):397–411.
Kyriakides TR, Zhu YH, Smith LT, Bain SD, Yang Z, Lin MT, et al. Mice that lack thrombospondin 2 display connective tissue abnormalities associated with disordered collagen fibrillogenesis, increased vascular density, and a bleeding diathesis. J Cell Biol. 1998;140(2):419–30.
Zhang N, Wu X, Zhang W, Sun Y, Yan X, Xu A, et al. Targeting thrombospondin-2 retards liver fibrosis by inhibiting TLR4-FAK/TGF-β signaling. JHEP Rep. 2024;6(3):101014.
Chen W, Wu X, Yan X, Xu A, Yang A, You H. Multi-transcriptome analyses reveal prioritized genes specifically associated with liver fibrosis progression. Am J Physiol Gastrointest Liver Physiol. 2019;316(6):G744–54.
Guha IN, Parkes J, Roderick P, Chattopadhyay D, Cross R, Harris S, et al. Non-invasive markers of fibrosis in NAFLD: validating the European Liver Fibrosis panel and exploring simple markers. Hepatology. 2008;47(2):455–60.
Nishikawa H, Enomoto H, Iwata Y, Nishimura T, Kita R, Kimura T, et al. Serum WFA+-M2BP as a diagnostic marker of liver fibrosis in NAFLD. Hepatol Res. 2016;46(10):1042–51.
Daniels SJ, Leeming DJ, Eslam M, Hashem AM, Nielsen MJ, Krag A, et al. ADAPT: an algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatology. 2019;69(3):1075–86.
Article Metrics
Abstract View
: 169 times
Download : 109 times
DOI: 10.24871/2632025263-267
Refbacks
- There are currently no refbacks.
